Long-Term Clinical Benefit in <i>EGFR</i>-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report.

导出 LinkOut

翻译打印收藏纠错

作者： Junru,Ye ^[1] ; Yutong,Ma ^[2] ; Qiuxiang,Ou ^[2] ; Junrong,Yan ^[3] ; Bin,Ye ^[3] ; Yuping,Li ^[1]

作者单位： Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. ^[1] Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China. ^[2] Medical Department, Nanjing Geneseeq Technology Inc., Nanjing, China. ^[3]

关键词 EGFR TKI PD-L1 adenocarcinoma case report squamous cell carcinoma

DOI 10.3389/fonc.2022.883367

PMID 35692748

发布时间 2023-11-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

883367页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Long-Term Clinical Benefit in <i>EGFR</i>-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Long-Term Clinical Benefit in <i>EGFR</i>-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除